Cargando…

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment

PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marbury, Thomas, Fox, Jerry, Kaelin, Byron, Pavliv, Leo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://www.ncbi.nlm.nih.gov/pubmed/28243060 http://dx.doi.org/10.2147/DDDT.S125459

Ejemplares similares

Dose comparison of conivaptan (Vaprisol(®)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics
por: Palmer, Biff F, et al.
Publicado: (2016)

Conivaptan and its role in the treatment of hyponatremia
por: Ghali, Jalal K, et al.
Publicado: (2009)

The Effect of Intravenous Conivaptan on Intraocular Pressure
por: Krishnankutty, Saritha Valsala, et al.
Publicado: (2016)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Conivaptan: Evidence supporting its therapeutic use in hyponatremia
por: Li-Ng, Melissa, et al.
Publicado: (2010)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Conivaptan: a step forward in the treatment of hyponatremia?
por: Hline, Su Su, et al.
Publicado: (2008)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
por: Hossain, Mohammad, et al.
Publicado: (2021)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative patients following major head and neck surgeries
por: Rajan, Sunil, et al.
Publicado: (2015)

Efficacy of vaptans for correction of postoperative hyponatremia: A comparison between single intravenous bolus conivaptan vs oral tolvaptan
por: Rajan, Sunil, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
por: Marbury, Thomas, et al.
Publicado: (2023)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
por: Chen, Xinhui, et al.
Publicado: (2021)

Pharmacokinetics of Gepotidacin in Renal Impairment
por: Hossain, Mohammad, et al.
Publicado: (2020)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function
por: Wicha, Wolfgang, et al.
Publicado: (2019)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice
por: Zeynalov, Emil, et al.
Publicado: (2017)

Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke
por: Zeynalov, Emil, et al.
Publicado: (2016)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice
por: Zeynalov, Emil, et al.
Publicado: (2015)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary Intensive Care Unit
por: Reddy, Sridhar Nagepalli Venkatarami, et al.
Publicado: (2016)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ngh2ps03h486aksn1o1b7blge7